Mangalam Drugs and Organics Ltd. | Small-cap | Healthcare
₹72.38
-0.40%
| Mangalam Drugs Stock Comparison:
Mangalam Drugs vs Sun PharmaceuticalMangalam Drugs vs Divi's LaboratoriesMangalam Drugs vs Innova CaptabMangalam Drugs vs Suven Life SciencesMangalam Drugs vs Gujarat ThemisMangalam Drugs vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 572.1M
Gross Profit 114.8M 20.07%
Operating Income -89.5M -15.65%
Net Income -138.0M -24.12%
EPS (Diluted) ₹-8.72

Balance Sheet Metrics

Total Assets 3.7B
Total Liabilities 2.2B
Shareholders Equity 1.5B
Debt to Equity 1.46

Cash Flow Metrics

Revenue & Profitability Trend

Mangalam Drugs Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i3.2B3.7B04.5B3.8B
Cost of Goods Sold i2.2B2.9B03.5B2.8B
Gross Profit i925.7M706.7M0987.4M976.7M
Gross Margin % i29.4%19.3%0.0%22.1%25.7%
Operating Expenses
Research & Development i----0
Selling, General & Administrative i179.7M164.5M154.4M150.6M134.3M
Other Operating Expenses i744.5M3.0K-1.0M581.2M1.7M
Total Operating Expenses i924.2M164.5M153.4M731.9M135.9M
Operating Income i173.9M10.5M0387.6M444.5M
Operating Margin % i5.5%0.3%0.0%8.7%11.7%
Non-Operating Items
Interest Income i578.0K958.0K3.0M06.2M
Interest Expense i111.8M104.1M072.0M63.2M
Other Non-Operating Income-----
Pre-tax Income i47.9M-110.7M0277.3M395.2M
Income Tax i-19.3M-20.0M080.8M115.5M
Effective Tax Rate % i-40.4%0.0%0.0%29.1%29.2%
Net Income i67.2M-90.7M0196.6M279.7M
Net Margin % i2.1%-2.5%0.0%4.4%7.4%
Key Metrics
EBITDA i325.0M140.4M109.9M450.9M550.2M
EPS (Basic) i₹4.25₹-5.73₹0.00₹12.42₹17.67
EPS (Diluted) i₹4.25₹-5.73₹0.00₹12.42₹17.67
Basic Shares Outstanding i1582824815828248158282481582824815828248
Diluted Shares Outstanding i1582824815828248158282481582824815828248

Income Statement Trend

Mangalam Drugs Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i25.9M11.8M26.8M19.5M5.8M
Short-term Investments i54.9M76.0K76.0K76.0K76.0K
Accounts Receivable i390.7M279.4M465.3M464.9M543.1M
Inventory i1.4B1.2B1.4B1.2B585.9M
Other Current Assets803.0K803.0K17.4M17.4M17.6M
Total Current Assets i2.0B1.8B2.1B1.9B1.3B
Non-Current Assets
Property, Plant & Equipment i316.9M388.6M351.3M262.9M184.4M
Goodwill i318.3M284.9M183.0M138.8M99.6M
Intangible Assets i318.3M284.9M183.0M138.8M99.6M
Long-term Investments-----
Other Non-Current Assets19.2M-8.8M24.1M-2.0K
Total Non-Current Assets i1.7B1.6B1.5B1.4B1.3B
Total Assets i3.7B3.3B3.6B3.3B2.6B
Liabilities
Current Liabilities
Accounts Payable i911.5M661.6M970.7M545.5M433.9M
Short-term Debt i844.8M885.0M630.4M575.9M596.4M
Current Portion of Long-term Debt-----
Other Current Liabilities73.6M6.8M6.0M13.9M17.6M
Total Current Liabilities i1.9B1.6B1.7B1.3B1.1B
Non-Current Liabilities
Long-term Debt i117.5M184.9M255.1M303.2M100.7M
Deferred Tax Liabilities i98.2M120.9M145.2M134.9M141.8M
Other Non-Current Liabilities13.5M19.3M-1.0K2.3M2.0K
Total Non-Current Liabilities i258.4M338.5M423.2M477.5M242.5M
Total Liabilities i2.2B2.0B2.1B1.8B1.3B
Equity
Common Stock i158.3M158.3M158.3M158.3M158.3M
Retained Earnings i928.4M867.3M1.0B1.0B817.9M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i1.5B1.4B1.5B1.5B1.3B
Key Metrics
Total Debt i962.3M1.1B885.5M879.0M697.1M
Working Capital i73.8M119.4M412.3M549.2M248.4M

Balance Sheet Composition

Mangalam Drugs Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i47.9M39.7M22.1M277.3M395.2M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i-172.9M47.5M-179.7M-296.1M-56.0M
Operating Cash Flow i24.3M159.8M-30.1M92.9M432.4M
Investing Activities
Capital Expenditures i-194.7M-118.3M-221.7M-275.3M-312.9M
Acquisitions i-----
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-194.7M-118.3M-221.7M-275.3M-312.9M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i-26.6M169.4M24.7M-40.9M93.2M
Free Cash Flow i223.9M-79.2M116.1M-19.6M-38.9M
Net Change in Cash i-197.0M210.9M-227.1M-223.3M212.8M

Cash Flow Trend

Mangalam Drugs Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 19.47
Price to Book 0.72
Price to Sales 0.39
PEG Ratio -0.03

Profitability Ratios

Profit Margin -3.27%
Operating Margin -15.65%
Return on Equity 4.51%
Return on Assets 1.83%

Financial Health

Current Ratio 1.04
Debt to Equity 64.59
Beta -0.19

Per Share Data

EPS (TTM) ₹-6.17
Book Value per Share ₹100.32
Revenue per Share ₹188.54

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
mangalam1.2B19.470.724.51%-3.27%64.59
Sun Pharmaceutical 4.0T37.735.4215.08%19.29%3.26
Divi's Laboratories 1.6T67.5710.4014.64%23.89%0.03
Innova Captab 48.6B37.445.0713.37%9.98%35.24
Suven Life Sciences 48.0B-28.3141.36-146.15%84.44%0.00
Gujarat Themis 46.2B103.1518.5519.64%30.17%12.27

Financial data is updated regularly. All figures are in the company's reporting currency.